Advaxis, Inc. Continues Collaboration with Former National Cancer Institute Vaccines Chief in New Position as Director of the Georgia Health Sciences University Cancer Center
3/20/2012 7:19:51 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced it will continue its collaboration with Dr. Samir N. Khleif, the former Chief of the Vaccines Section at the National Cancer Institute (NCI), at his new position of Director of the Georgia Health Sciences University Cancer Center at Augusta, Georgia. While at NCI, Dr. Khleif designed many of the early cancer vaccine clinical trials targeting specific genetic changes in cancer that might enable the immune system to attack cancer cells, and identified mechanisms used by tumors to defend against immune attack. The Khleif lab will continue to elaborate the molecular immunologic mechanisms by which live, attenuated strains of Listeria monocytogenes can effect therapeutic changes in cancer and other diseases.